Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes

Yong Ho Lee, Byung Wan Lee, Hea Jin Kwon, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The aims of this study are to investigate not only the glucose-lowering effectiveness of twice-daily premixed insulin lispro 25 (Humalog® Mix25™, Eli Lilly and Co., Indianapolis, IN), but also the optimal divided ratio of total Mix25 dose in Korean patients with poorly controlled type 2 diabetes. Subjects and Methods: In this retrospective study, we retrieved data for subjects who were on intensive insulin therapy with twice-daily Mix25 regimen for at least 24 weeks. Changes of hemoglobin A1c (HbA 1c) and other clinical and laboratory parameters were evaluated. Two groups were defined according to dose ratio of pre-breakfast to pre-dinner insulin at 24 weeks: Group I, pre-breakfast:pre-dinner insulin dose ratio=50:50; Group II, ratio=53:47-75:25. Results: In total, 143 subjects were ultimately analyzed in this study. Twice-daily Mix25 significantly improved HbA 1c levels from 10.1% to 7.7%, and 34% of patients had reached the target glycemic goal (HbA 1c<7%) after 24 weeks. Compared with Group I, a significant reduction in HbA 1c (Group I vs. Group II, -1.9±0.3% vs. -2.8±0.3%, P=0.02) and a larger proportion of subjects with HbA 1c<7% (23.2% vs. 46.7%, P=0.01) were observed in subjects in Group II. Among clinical and laboratory factors, duration of diabetes (odd ratios [OR]=0.93, 95% confidence interval [CI] 0.86-0.99, P=0.04) and history of sulfonylurea use (OR=0.27, 95% CI 0.10-0.72, P=0.01) were independently associated with achieving target HbA 1c levels less than 7%. Conclusions: Twice-daily Mix25 is an effective option for Korean subjects with type 2 diabetes having uncontrolled hyperglycemia. A higher pre-breakfast/pre-dinner dose ratio (53:47-75:25) might be taken into consideration as an initial protocol to accomplish better glycemic control in twice-daily Mix25.

Original languageEnglish
Pages (from-to)508-514
Number of pages7
JournalDiabetes Technology and Therapeutics
Volume14
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Biphasic Insulins
Type 2 Diabetes Mellitus
Hemoglobins
Glucose
Breakfast
Meals
Insulin
Odds Ratio
Insulin Lispro
Confidence Intervals
Hyperglycemia
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this

@article{1a08a6b694a6498cb6dd4741a71756f8,
title = "Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes",
abstract = "Background: The aims of this study are to investigate not only the glucose-lowering effectiveness of twice-daily premixed insulin lispro 25 (Humalog{\circledR} Mix25™, Eli Lilly and Co., Indianapolis, IN), but also the optimal divided ratio of total Mix25 dose in Korean patients with poorly controlled type 2 diabetes. Subjects and Methods: In this retrospective study, we retrieved data for subjects who were on intensive insulin therapy with twice-daily Mix25 regimen for at least 24 weeks. Changes of hemoglobin A1c (HbA 1c) and other clinical and laboratory parameters were evaluated. Two groups were defined according to dose ratio of pre-breakfast to pre-dinner insulin at 24 weeks: Group I, pre-breakfast:pre-dinner insulin dose ratio=50:50; Group II, ratio=53:47-75:25. Results: In total, 143 subjects were ultimately analyzed in this study. Twice-daily Mix25 significantly improved HbA 1c levels from 10.1{\%} to 7.7{\%}, and 34{\%} of patients had reached the target glycemic goal (HbA 1c<7{\%}) after 24 weeks. Compared with Group I, a significant reduction in HbA 1c (Group I vs. Group II, -1.9±0.3{\%} vs. -2.8±0.3{\%}, P=0.02) and a larger proportion of subjects with HbA 1c<7{\%} (23.2{\%} vs. 46.7{\%}, P=0.01) were observed in subjects in Group II. Among clinical and laboratory factors, duration of diabetes (odd ratios [OR]=0.93, 95{\%} confidence interval [CI] 0.86-0.99, P=0.04) and history of sulfonylurea use (OR=0.27, 95{\%} CI 0.10-0.72, P=0.01) were independently associated with achieving target HbA 1c levels less than 7{\%}. Conclusions: Twice-daily Mix25 is an effective option for Korean subjects with type 2 diabetes having uncontrolled hyperglycemia. A higher pre-breakfast/pre-dinner dose ratio (53:47-75:25) might be taken into consideration as an initial protocol to accomplish better glycemic control in twice-daily Mix25.",
author = "Lee, {Yong Ho} and Lee, {Byung Wan} and Kwon, {Hea Jin} and Kang, {Eun Seok} and Cha, {Bong Soo} and Lee, {Hyun Chul}",
year = "2012",
month = "6",
day = "1",
doi = "10.1089/dia.2011.0208",
language = "English",
volume = "14",
pages = "508--514",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes. / Lee, Yong Ho; Lee, Byung Wan; Kwon, Hea Jin; Kang, Eun Seok; Cha, Bong Soo; Lee, Hyun Chul.

In: Diabetes Technology and Therapeutics, Vol. 14, No. 6, 01.06.2012, p. 508-514.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes

AU - Lee, Yong Ho

AU - Lee, Byung Wan

AU - Kwon, Hea Jin

AU - Kang, Eun Seok

AU - Cha, Bong Soo

AU - Lee, Hyun Chul

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background: The aims of this study are to investigate not only the glucose-lowering effectiveness of twice-daily premixed insulin lispro 25 (Humalog® Mix25™, Eli Lilly and Co., Indianapolis, IN), but also the optimal divided ratio of total Mix25 dose in Korean patients with poorly controlled type 2 diabetes. Subjects and Methods: In this retrospective study, we retrieved data for subjects who were on intensive insulin therapy with twice-daily Mix25 regimen for at least 24 weeks. Changes of hemoglobin A1c (HbA 1c) and other clinical and laboratory parameters were evaluated. Two groups were defined according to dose ratio of pre-breakfast to pre-dinner insulin at 24 weeks: Group I, pre-breakfast:pre-dinner insulin dose ratio=50:50; Group II, ratio=53:47-75:25. Results: In total, 143 subjects were ultimately analyzed in this study. Twice-daily Mix25 significantly improved HbA 1c levels from 10.1% to 7.7%, and 34% of patients had reached the target glycemic goal (HbA 1c<7%) after 24 weeks. Compared with Group I, a significant reduction in HbA 1c (Group I vs. Group II, -1.9±0.3% vs. -2.8±0.3%, P=0.02) and a larger proportion of subjects with HbA 1c<7% (23.2% vs. 46.7%, P=0.01) were observed in subjects in Group II. Among clinical and laboratory factors, duration of diabetes (odd ratios [OR]=0.93, 95% confidence interval [CI] 0.86-0.99, P=0.04) and history of sulfonylurea use (OR=0.27, 95% CI 0.10-0.72, P=0.01) were independently associated with achieving target HbA 1c levels less than 7%. Conclusions: Twice-daily Mix25 is an effective option for Korean subjects with type 2 diabetes having uncontrolled hyperglycemia. A higher pre-breakfast/pre-dinner dose ratio (53:47-75:25) might be taken into consideration as an initial protocol to accomplish better glycemic control in twice-daily Mix25.

AB - Background: The aims of this study are to investigate not only the glucose-lowering effectiveness of twice-daily premixed insulin lispro 25 (Humalog® Mix25™, Eli Lilly and Co., Indianapolis, IN), but also the optimal divided ratio of total Mix25 dose in Korean patients with poorly controlled type 2 diabetes. Subjects and Methods: In this retrospective study, we retrieved data for subjects who were on intensive insulin therapy with twice-daily Mix25 regimen for at least 24 weeks. Changes of hemoglobin A1c (HbA 1c) and other clinical and laboratory parameters were evaluated. Two groups were defined according to dose ratio of pre-breakfast to pre-dinner insulin at 24 weeks: Group I, pre-breakfast:pre-dinner insulin dose ratio=50:50; Group II, ratio=53:47-75:25. Results: In total, 143 subjects were ultimately analyzed in this study. Twice-daily Mix25 significantly improved HbA 1c levels from 10.1% to 7.7%, and 34% of patients had reached the target glycemic goal (HbA 1c<7%) after 24 weeks. Compared with Group I, a significant reduction in HbA 1c (Group I vs. Group II, -1.9±0.3% vs. -2.8±0.3%, P=0.02) and a larger proportion of subjects with HbA 1c<7% (23.2% vs. 46.7%, P=0.01) were observed in subjects in Group II. Among clinical and laboratory factors, duration of diabetes (odd ratios [OR]=0.93, 95% confidence interval [CI] 0.86-0.99, P=0.04) and history of sulfonylurea use (OR=0.27, 95% CI 0.10-0.72, P=0.01) were independently associated with achieving target HbA 1c levels less than 7%. Conclusions: Twice-daily Mix25 is an effective option for Korean subjects with type 2 diabetes having uncontrolled hyperglycemia. A higher pre-breakfast/pre-dinner dose ratio (53:47-75:25) might be taken into consideration as an initial protocol to accomplish better glycemic control in twice-daily Mix25.

UR - http://www.scopus.com/inward/record.url?scp=84861979805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861979805&partnerID=8YFLogxK

U2 - 10.1089/dia.2011.0208

DO - 10.1089/dia.2011.0208

M3 - Article

C2 - 22376081

AN - SCOPUS:84861979805

VL - 14

SP - 508

EP - 514

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 6

ER -